AIM To explore the clinical efficacy of Jia Wei Jingui Shengqi Pill(JWJSP)as a novel prophylaxis regimen for haemorrhagic cystitis(HC)in patients undergoing haploidentical hematopoietic stem cell transplantation.METHODS A prospective cohort analysis was conducted on 65 patients with hematological malignancies who underwent haploidentical hematopoietic stem cell transplantation from January 2020 to October 2023.Patients were divided into a JWJSP group(31 cases)and a control group(34 cases).The JWJSP group was administered JWJSP 5 g orally twice daily,while the control group received no specific prophylactic measures.The cumulative incidence of HC,clinical characteristics,and the positive rate of viruria in both groups were compared.The median follow-up duration was 277(65,624)days.RESULTS The cumulative incidence of HC in the JWJSP group was(29±3)％,significantly lower than that in the control group(53±3)％(P＜0.01).There was no significant difference in the median onset time and duration of HC between the two groups(P＞0.05).The median onset time of HC in the two groups of patients was 26(20,32)days and 37(25,45)days after transplantation,respectively,and the median duration was 13(10,24)days and 16(14,53)days,respectively,with no significant difference(P＞0.05).The positive rate of BKV viruria in the JWJSP group after transplantation was 42％,significantly lower than that in the control group(68％)(P＜0.05).CONCLUSION Prophylaxis with JWJSP may decrease the infection rate of BKV in urine and the overall incidence of HC in patients undergoing haploidentical hematopoietic stem cell transplantation.
维普
万方数据